Insulin-like growth factors (IGFs) system and tumors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F16%3A10335292" target="_blank" >RIV/00669806:_____/16:10335292 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/16:10335292

Výsledek na webu

<a href="http://www.cupress.cuni.cz/ink2_stat/dload.jsp?prezMat=74633" target="_blank" >http://www.cupress.cuni.cz/ink2_stat/dload.jsp?prezMat=74633</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Insulin-like growth factors (IGFs) system and tumors

Popis výsledku v původním jazyce

The interaction between growth factors and cancer incidence and development has been discussed recently. Insulin-like growth factors (IGF, insulin-like growth factors, formerly named somatomedines) are peptides, that participate on growth regulation, metabolism regulation, cell survival and differentiation. They are regulated by growth hormone (GH). IGFs are synthesized in liver and they occur in other body fluids. IGFBPs occur in different body fluids like serum, amniotic fluid and cerebrospinal fluid. IGFBPs are synthesized in liver. These binding proteins serve as storage of IGFs in intercellular space. Effect of IGF1 and IGF2 on cell is mediated by receptors. Signal transduction follows the successful binding to the receptor via signal intracellular pathway - i.e. cascade of enzymes and its substrates. Based on knowledge of IGF1 and IGF2 effect on cells it is assumed that high IGFs serum levels increase the risk for cancer development. They also stimulate proliferation and risk of malignant transformation. High serum levels of binding proteins IGFBPs, particularly dominant serum binding protein IGFBP3, should decrease the risk and inhibit the cellular growth. It is assumed that malignant transformation of the cells can occur independently from serum levels of IGFs in case of presence of functional IGF1R. Recent clinical studies confirmed that high circulating IGF1 concentrations and low IGFBP3 serum levels are related to increase risk for cancer diseases. Negative correlation between IGFBP3 levels and risk of cancer diseases corresponds to protective role of IGFBP3.

Název v anglickém jazyce

Insulin-like growth factors (IGFs) system and tumors

Popis výsledku anglicky

The interaction between growth factors and cancer incidence and development has been discussed recently. Insulin-like growth factors (IGF, insulin-like growth factors, formerly named somatomedines) are peptides, that participate on growth regulation, metabolism regulation, cell survival and differentiation. They are regulated by growth hormone (GH). IGFs are synthesized in liver and they occur in other body fluids. IGFBPs occur in different body fluids like serum, amniotic fluid and cerebrospinal fluid. IGFBPs are synthesized in liver. These binding proteins serve as storage of IGFs in intercellular space. Effect of IGF1 and IGF2 on cell is mediated by receptors. Signal transduction follows the successful binding to the receptor via signal intracellular pathway - i.e. cascade of enzymes and its substrates. Based on knowledge of IGF1 and IGF2 effect on cells it is assumed that high IGFs serum levels increase the risk for cancer development. They also stimulate proliferation and risk of malignant transformation. High serum levels of binding proteins IGFBPs, particularly dominant serum binding protein IGFBP3, should decrease the risk and inhibit the cellular growth. It is assumed that malignant transformation of the cells can occur independently from serum levels of IGFs in case of presence of functional IGF1R. Recent clinical studies confirmed that high circulating IGF1 concentrations and low IGFBP3 serum levels are related to increase risk for cancer diseases. Negative correlation between IGFBP3 levels and risk of cancer diseases corresponds to protective role of IGFBP3.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/EE2.3.20.0040" target="_blank" >EE2.3.20.0040: Molekulární genetika nádorových a kardiovaskulárních chorob</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Plzeňský lékařský sborník

ISSN

0551-1038

e-ISSN

—

Svazek periodika

2016

Číslo periodika v rámci svazku

82

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

17-23

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—